N/A N=45 The Evaluation of a New Nasal Mask for the Treatment of Obstructive Sleep Apnea
Obstructive Sleep Apnea
Primary: Number of Participants Objective Trial Mask Performance — 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=33 A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness
Narcolepsy
Primary: Change From Baseline in the Average Sleep Latency Time (in Minutes) as Determined From the Maintenance of Wakefulness Test (MWT) Following Two Weeks of Treatment With…
Phase 3 N=42 Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan
Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease
Primary: Mean Hb Level of Week 20 and Week 24 — 11.35 g/dL
N/A N=21 Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Measurement of Eosinophilic Degranulating Protein Concentration — 456.5 ng/mL
N/A N=97 Stand if You Can: A Standing Intervention in Long Term Care
Frailty · Sedentary Behavior · Physical Disability
Primary: Changes in Walking Speed — 0.34; 0.43; 0.35; 0.40 m/s
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
Phase 4 N=49 Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation
Asthma
Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted
N/A N=366 Incidence of Postoperative Residual Neuromuscular Blockade in Portugal
Residual Neuromuscular Blockade · Residual Paralysis, Post-Anesthesia · Observational Study
Primary: Percentage of Patients With Postoperative Residual Neuromuscular Blockade — 20 Participants
Phase 2 N=524 A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
Essential Hypertension
Primary: Core Period: Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 Last Observation Carried Forward (LOCF), as Measured by Office Blood…
Phase 4 N=3 The Role of Orexin in Human Panic Disorder
Panic Disorder
Primary: Change in Orexin Levels (Blood) +1 Minute
Phase 3 N=258 A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) for ELX/TEZ/IVA Group — 3.7 percentage points
Phase 2 N=49 Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Macular Edema
Primary: Safety Tolerability: Number of Ocular and Non-ocular TEAEs — 5; 22; 22 participants
N/A N=102 Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD
Primary: Number of Subjects With Incidence of Study Product Emergent Adverse Events (AEs) and Any Serious Adverse Events (SAEs) — 10; 8; 13; 2 participants
Phase 3 N=307 DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
Bacterial Vaginosis
Primary: Number of Patients With Clinical Cure at the TOC Visit (Day 21-30). — 86; 21 Participants
N/A N=635 A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
Posttraumatic Stress Disorder · Depression · Alcohol-Related Disorders
Primary: Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury — -1.65; 0.08; -4.02; -1.44 score on a scale